Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST Extension study of oral ZPL389 in adults with atopic dermatitis
NL-OMON49671Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adriforant in atopic dermatitis (AD) (2 arms), sponsored by Novartis. Primary endpoint: Short-term and long-term safety. Started Mar 2020; status: completed.
02
Drugs
adriforant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON49671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49671.